ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Sponsor

Enliven Therapeutics (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05650879

Collaborator

(none)

178

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to test ELVN-002 in people with cancers that ha an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses. A second main question is to evaluate the concentration of ELVN-002 in the blood at different doses and to see how this correlates with safety and see how the concentration of drug changes over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-small cell lung cancer.

Condition or Disease	Intervention/Treatment	Phase
HER2 Mutant Non-small Cell Lung Cancer HER2-positive Metastatic Breast Cancer HER2 Gene Mutation HER2 Amplification	Drug: ELVN-002 Drug: Fam-Trastuzumab Deruxtecan-Nxki Drug: Trastuzumab emtansine	Phase 1

Detailed Description

There are 4 parts to the trial. Part 1 is a dose escalation with ELVN-002 monotherapy for people with advanced stage solid tumors that have a HER2 mutation, amplification or high HER2 over-expression. Part 2 is an ELVN-002 monotherapy dose exploration where additional people may be enrolled at dose levels that have cleared the dose escalation in Part 1 to further evaluate the safety, tolerability, pharmacokinetics and clinical activity. Part 3 is a dose expansion of ELVN-002 monotherapy which will enroll up to 40 patients people with advanced stage HER2 mutant non-small cell lung cancer. Patients in Part 3 will be randomized 1:1 to receive one of two dose levels.

Part 4 is a combination dose escalation where, based on the results of Part 1 and 2, a combination of ELVN-002 and either fam-trastuzumab deruxtecan-nxki (in HER2 mutant non-small cell lung cancer) or trastuzumab emtansine (in HER2 positive breast cancer) will be evaluated for safety and tolerability.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

178 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Intervention Model Description:

Phase 1 will be a dose escalation monotherapy according to the Bayesian Optimal Interval Design model Phase 1b will be a dose expansion: up to 40 patients randomized between 2 dose levelsPhase 1 will be a dose escalation monotherapy according to the Bayesian Optimal Interval Design model Phase 1b will be a dose expansion: up to 40 patients randomized between 2 dose levels

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer

Anticipated Study Start Date :

Mar 1, 2023

Anticipated Primary Completion Date :

Jul 1, 2026

Anticipated Study Completion Date :

Jul 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Phase 1a Monotherapy Dose Escalation ELVN-002 will be administered either once or twice daily. Each cohort of patients will receive a higher dose. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.	Drug: ELVN-002 capsule
Experimental: Phase 1a Monotherapy Dose Exploration ELVN-002 will be administered either once or twice daily. A maximum of 30 patients will enroll in this arm. A maximum of 10 patients may be enrolled at a single dose. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.	Drug: ELVN-002 capsule
Experimental: Phase 1b Monotherapy Dose Expansion ELVN-002 will be administered either once or twice daily. A maximum of 40 patients will enroll in this arm. Patients will be randomized 1:1 to one of two dose levels. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.	Drug: ELVN-002 capsule
Experimental: Phase 1a Combination Dose Escalation with T-DXd ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 5.4mg/kg of intravenous T-DXd once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.	Drug: ELVN-002 capsule Drug: Fam-Trastuzumab Deruxtecan-Nxki intravenous Other Names: Enhertu T-DXd
Experimental: Phase 1a Combination Dose Escalation with T-DM1 ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 5.4mg/kg of intravenous T-DM1 once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.	Drug: ELVN-002 capsule Drug: Trastuzumab emtansine intravenous Other Names: Kadcyla T-DM1

Outcome Measures

Primary Outcome Measures

Incidence of dose limiting toxicities in Phase 1a monotherapy [21 days]
Incidence of adverse events in Phase 1a monotherapy [24 months]
incidence of laboratory abnormalities in Phase 1a monotherapy [24 months]
incidence of ECG abnormalities in Phase 1a monotherapy [24 months]
incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd) [42 days]
Incidence of adverse events in Phase 1a combination with T-DXd [24 months]
incidence of laboratory abnormalities in Phase 1a combination with T-DXd [24 months]
incidence of ECG abnormalities in Phase 1a combination with T-DXd [24 months]
incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1) [42 days]
Incidence of adverse events in Phase 1a combination with T-DM1 [24 months]
incidence of laboratory abnormalities in Phase 1a combination with T-DM1 [24 months]
incidence of ECG abnormalities in Phase 1a combination with T-DM1 [24 months]
Incidence of adverse events in Phase 1b monotherapy [24 months]
incidence of laboratory abnormalities in Phase 1b monotherapy [24 months]
incidence of ECG abnormalities in Phase 1b monotherapy [24 months]

Secondary Outcome Measures

Objective Response rate in Phase 1a monotherapy [24 months]
For patients with measurable disease at baseline, confirmed response per RECIST 1.1
Objective response rate in Phase 1b monotherapy [24 months]
Confirmed response per RECIST 1.1
Duration of response in Phase 1b monotherapy [24 months]
The time from the first response to progression or death per RECIST 1.1
Brain metastases response in Phase 1b monotherapy [24 months]
for patients with measurable brain metastases at baseline, the percent of patients who have a confirmed response per RECIST 1.1
PK parameter of area under the curve of ELVN-002 in Phase 1a monotherapy [21 days]
the concentration of ELVN-002 measured in the blood over 24 hours at steady state
PK parameter of maximum concentration of ELVN-002 in Phase 1a monotherapy [21 days]
the maximum concentration of ELVN-002 measured in the blood at any time point at steady state
PK parameter of terminal half life of ELVN-002 in Phase 1a monotherapy [21 days]
the half life of ELVN-002 calculated from the concentration of ELVN-002 in blood
PK parameter of area under the curve of ELVN-002 in Phase 1b monotherapy [21 days]
the concentration of ELVN-002 measured in the blood over 24 hours at steady state
PK parameter of maximum concentration of ELVN-002 in Phase 1b monotherapy [21 days]
the maximum concentration of ELVN-002 measured in the blood at any time point at steady state
PK parameter of terminal half life of ELVN-002 in Phase 1b monotherapy [21 days]
the half life of ELVN-002 calculated from the concentration of ELVN-002 in blood

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Phase 1a Monotherapy Dose Escalation and Exploration:

Pathologically documented advanced stage solid tumor
Progressed following all standard treatment or not appropriate for standard treatment
HER2 mutation, HER2 amplification or HER2 positive based on local testing

Phase 1b Monotherapy

Pathologically documented unresectable and/or metastatic non-squamous NSCLC
HER2 mutation identified by tissue (fresh or archival) or ctDNA. Local testing for up to 20 patients the remainder centrally confirmed.
Measurable disease
No known epidermal growth factor receptor (EGFR), ROS1, anaplastic lymphoma kinase (ALK), or BRAF V600E mutation
Progressed after receiving at least 1 prior systemic therapy including a platinum-based chemotherapy with or without immunotherapy, or not appropriate for standard treatment.
No prior HER2 tyrosine kinase inhibitor. Prior HER2 directed antibodies or anti-body drug conjugates are allowed
No limit on prior number of therapies

Phase 1a Combination with T-DXd

Pathologically documented advanced stage NSCLC
Progressed after receiving at least 1 prior systemic therapy.
HER2 mutation based on local/historical testing of tissue or circulating tumor DNA
No known EGFR, ROS1, ALK, or BRAF V600E mutation
No prior T-DXd
No clinically severe pulmonary compromise
No limit on prior number of therapies

Phase 1a Combination Breast Cancer

Documented HER2 positive (Immunohistochemical [IHC] 3+ or IHC2+/in situ hybridization (ISH+) breast cancer
Must have previously received trastuzumab, a taxane, and T-DXd (if available and appropriate) in the metastatic setting.
No limit on prior number of therapies
No prior T-DM1

All Phases

Eastern Cooperative Oncology Group performance status of 0-1
Left ventricular ejection fraction ≥ 50%
Platelet count ≥ 100 x 109/L
Hemoglobin ≥ 8.5 g/dL
Absolute neutrophil count ≥1.0 x 109/L
Total bilirubin < 1.5 times upper limit of normal range (ULN), except for patients with Gilbert's syndrome
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 3 times ULN. In the setting of liver metastases < 5 times ULN.
Creatinine clearance ≥ 60 mL/minute

Exclusion Criteria All Phases:

Severe cardiac arrhythmias, requiring treatment, symptomatic congestive heart failure, myocardial infarction within 28 days prior to first dose, or unstable angina.
Another active malignancy within 2 years except basal cell skin cancer and carcinoma in situ treated curatively
Active or chronic liver disease
Active infection requiring systemic therapy within 14 days before the first dose
Brain lesion requiring immediate local therapy
Leptomeningeal disease
Uncontrolled seizures
Corrected QT interval (QTc) of >470 milliseconds (ms) females or >450 ms for males by Fridericia (QTcF)